publication date: Jul. 1, 2016
Soft Tissue Sarcoma Phase III Eribulin Trial Boosts OS in Liposarcoma Patients
Data from a phase III trial evaluating eribulin in liposarcoma demonstrated a significant improvement in overall survival.
Patients receiving eribulin had an overall survival of 15.6 months, compared to 8.4 months in patients receiving dacarbazine (HR=0.51; p=0.001), according to pre-planned tumor subtype analyses. Progression-free survival was 2.9 months in the eribulin arm compared to 1.7 months in the dacarbazine arm (HR=0.52; p=0.002). The data were presented at the ASCO annual meeting in Chicago.
These tumor subtype-specific analyses examined 143 patients with liposarcoma, representing 32 percent of the total study population. An overall survival benefit was observed with eribulin versus dacarbazine regardless of liposarcoma histology: dedifferentiated is 18.0 vs 8.1 months (HR=0.43); myxoid/round cell is 13.5 vs 9.6 months (HR=0.79); and pleomorphic is 22.2 vs 6.7 months (HR=0.18).
The trial, Study 309, is a randomized, open-label study comparing the efficacy and safety of eribulin to dacarbazine in 452 adult patients with leiomyosarcomas or liposarcomas. Patients with locally advanced or relapsed and metastatic soft tissue sarcomas who showed disease progression following standard therapies must have included an anthracycline and at least one other additional regimen.
Eribulin has a toxicity profile consistent with prior experience, with no unexpected or new safety findings. Treatment with eribulin is well tolerated and the most common all grade … Continue reading CCL June 2016 – Phase III Eribulin Trial Boosts OS in Liposarcoma Patients
To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us
and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.